← Back to Search

Janus Kinase (JAK) Inhibitor

Deucravacitinib for Psoriasis (ARTISTYK Trial)

Phase 4
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Moderate-to-severe plaque psoriasis as defined by static Physician Global Assessment (s-PGA) ≥ 3 at the Screening Visit and Day 1
≥ 3% of Body Surface Area (BSA) involvement at the Screening Visit and Day 1
Must not have
Non-plaque psoriasis (that is, guttate, pustular, erythrodermic, palmoplantar only involvement or drug-induced psoriasis) at Screening Visit or Day 1
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved

Summary

This trial studies how a drug can help improve quality of life for people with psoriasis.

Who is the study for?
This trial is for men and women who have had stable plaque psoriasis for at least 6 months, with moderate-to-severe symptoms. Participants should have a noticeable impact on their quality of life due to psoriasis and be suitable candidates for phototherapy or systemic therapy, with at least 3% body surface area affected.
What is being tested?
The study is testing the effects of Deucravacitinib on improving the quality of life in people with plaque psoriasis compared to a placebo. It's set in a real-world community setting rather than a hospital.
What are the potential side effects?
While specific side effects are not listed here, Deucravacitinib may cause typical drug-related adverse reactions which can include gastrointestinal issues, headaches, potential skin reactions, or other immune-mediated conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have moderate-to-severe plaque psoriasis.
Select...
At least 3% of my skin is affected by my condition.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My psoriasis is not plaque type but another form like guttate or pustular.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2023 Phase 2 trial • 67 Patients • NCT04877990
25%
COVID-19
13%
Pneumonia
13%
Nasopharyngitis
8%
Cough
8%
Pyrexia
8%
Mouth ulceration
8%
Upper respiratory tract infection
4%
Urinary tract infection
4%
Small intestinal obstruction
4%
Sepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
CROHN'S DISEASE
ULCERATIVE COLITIS

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DeucravacitinibExperimental Treatment1 Intervention
Group II: Placebo then DeucravacitinibPlacebo Group2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
2021
Completed Phase 4
~320

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,696 Previous Clinical Trials
4,098,891 Total Patients Enrolled
39 Trials studying Psoriasis
21,328 Patients Enrolled for Psoriasis

Media Library

Deucravacitinib (Janus Kinase (JAK) Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05701995 — Phase 4
Psoriasis Research Study Groups: Deucravacitinib, Placebo then Deucravacitinib
Psoriasis Clinical Trial 2023: Deucravacitinib Highlights & Side Effects. Trial Name: NCT05701995 — Phase 4
Deucravacitinib (Janus Kinase (JAK) Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05701995 — Phase 4
~64 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top